Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Shares of Athenahealth, Inc. ( ATHN - Analyst Report ) hit a new 52-week high of $99.79, before closing on Friday, Mar 18 at $97.82. The share price of this leading provider of Electronic Health Care (EHR) solutions for ambulatory care and hospital settings has been on an upward trend since it reported fourth quarter 2012 results on Feb 7.
Drivers that Triggered Momentum
A positive fourth quarter earnings surprise and improved business prospects following the acquisition of Epocrates facilitated the shares of Athenahealth to gather momentum and achieve a new high.
Athenahealth reported fourth quarter adjusted earnings per share of 18 cents beating the Zacks Consensus Estimate of 16 cents. Reported net income in the fourth quarter increased 11.5% year over year to $5.9 million (or 16 cents per share).
Athenahealth revealed, earlier in Mar, that it accomplished the takeover of Epocrates, a pioneer of mobile health workflows and point-of-care (POC) health apps. The composite company is well placed to bring to market fresh mobile workflows to meet the data requirements of clinicians. Furthermore, Athenahealth’s provider network of 40,000 now encompasses over a million clinicians from the Epocrates set up.
Following several prominent client wins, Athenahealth is better positioned to win deals in the enterprise segment.
On the negative side, the Stimulus which promoted EHR is gradually being withdrawn. While greenfield opportunities are shrinking, the replacement market is nonetheless growing.
Stock’s Key Indicators
Athenahealth is more expensive than its peer group as per most metrics such as forward P/E, price-to-sales ratio and price-to-book ratio. However, given the company’s higher long-term growth rate of 25% versus the peer group at 19.1%, the premium valuation may well be justified.
About the Company
Athenahealth’s web-based deployment provides a low-cost scalable service while its flexible rules engine leads to higher efficiency in claims settlement. The Software-as-a-Service (SaaS)-based approach allows for a more flexible delivery mechanism that helps Athenahealth win deals. The company has traditionally enjoyed high customer satisfaction rates, which facilitates a larger number of referrals.
Athenahealth’s unique business model makes it a strong provider of RCM services (athenaCollector) designed for small physician practices. Its EHR product (athenaClinicals) is a key player in ambulatory settings. We believe that sales of athenaClinicals are likely to remain robust. In addition, the company will harness its newer products, namely athenaCommunicator and athenaCoordinator.
Athenahealth should benefit from its extensive athenaCollector client base, as only a minority of its subscriber base also utilizes athenaClinicals. Cross selling represents a real growth opportunity in the near term. In this regard, Athenahealth has made rapid strides in capturing the EHR business of physician practices. However, this segment is shrinking, as hospitals increasingly absorb physician’s medical practices. Competition is intense with established players such as Cerner Corporation ( CERN - Analyst Report ) and Allscripts Healthcare Solutions, Inc. ( MDRX - Analyst Report ) .
The company has a Zacks Rank #3 (Hold). We are more positive about Merge Healthcare Incorporated ( MRGE - Analyst Report ) , which carries a Zacks Rank #2 (Buy) and is expected to do well.
Read the full Analyst Report on CERN
Read the full Analyst Report on ATHN
Read the full Analyst Report on MDRX
Read the full Analyst Report on MRGE